Evecxia Licenses Additional IP from NUS, NUH and NTU in Singapore

Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, today announced that it has licensed exclusive, world-wide rights to develop and commercialize novel formulations for improving the bioavailability and pharmacokinetics of 5-hydroxytryptophan (5-HTP) from:

  • National University of Singapore (NUS), acting through its Duke-NUS Medical School (Duke-NUS)
  • National University Hospital (NUH)
  • Nanyang Technological University, Singapore (NTU), through its innovation and enterprise company NTUitive Pte. Ltd

The joint intellectual property licensed from NUS-NUH-NTU was developed using funding from the National Health Innovation Centre Singapore (NHIC) under its Innovation to Develop (I2D) grant scheme.

This license agreement with DUKE-NUS, NUH and NTUitive strengthens our patent portfolio with additional protection, geographic coverage, and years of exclusivity to EVX-101, our lead product candidate, said John Kaiser, CEO of Evecxia.

Under the terms of the agreement, Evecxia will immediately assume full development and commercialization of EVX-101 and any other product candidates emanating from the license agreement with Duke-NUS, NUH and NTU. In addition to an upfront licensing fee Duke-NUS, NUH and NTU will receive milestone and low single-digit royalty payments.

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 

About Evecxia

Evecxia Inc. is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuropsychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen. Evecxia is located in the Research Triangle Park, NC. Evecxia’s primary mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal.

Evecxia is the first company dedicated to realizing the therapeutic potential of 5-HTP via specialized prescription combinations and drug delivery dosage forms.

About EVX-101

EVX-101 is a proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa. Initially, EVX-101 will be developed and positioned as a first-choice adjunctive treatment in depressed patients responding inadequately to conventional antidepressants. As an antidepressant, the development of EVX-101, a new chemical entity (NCE), is uniquely de-risked because the therapeutic mechanismelevating extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressantsenjoys human proof-of-concept (POC) for efficacy and safety.

For more information about the Company and its product candidate, visit www.evecxia.com or contact [email protected].

Evecxia, Inc.
John Kaiser, CEO
[email protected]

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 
Close
Stay Updated To Save Money & Time. Join Our Free Newsletter. 
. Indepth Analysis & Opinion       Interviews          . Exclusive Reports 
. Free Digital Magazines        . News & updates        . Event Invitations
& Much More Delivered To Your Inbox For Free. 
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.
 
Close